“A 2026 Nature study integrated mutational signatures across prostate-cancer genomes to characterize mutational processes and explore clinical associations.”

Checks out so far. 2 hold up so far.

0.8615 under ledger-default@0.3.0 at snapshot 27745 for all claims together. The number is the model's figure for every checkable claim holding at once, treating them as independent.

The statement as a whole, read from the 2 claims below. Each claim is scored on its own; this reading only counts them. Provisional until audited.

Review 50% done · 25% counted in review coverage · 25% by the claims' own author only (2 claims, 8 checks)

Share:

Checked in Galedra: score 0.86, mostly supported · not yet reviewed by anyone else “A 2026 Nature study integrated mutational signatures across prostate-cancer genomes to characterize mutational processes and explore clinical associations.” https://galedra.org/investigations/01a0ea7a-0dc0-768f-b4a0-edb5c6147f76

“In a study of 959 primary prostate-cancer donors, eight integrated mutational footprints collectively explained the mutational processes in 85% of primary prostate-cancer genomes; four footprints present in 37% of primary tumours were associated with shorter time to metastasis.”

Supported · 0.9781 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

2 of 4 review checks done · 1 counted · 1 by the author only

See the evidence · Claim card

“In a retrospective metastatic prostate-cancer cohort, among cases classified as IMF6-high, androgen-receptor pathway inhibitor treatment was associated with lower treatment-failure risk than taxane treatment (HR 0.21, 95% CI 0.05–0.79, P = 0.021).”

Supported · 0.8808 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

2 of 4 review checks done · 1 counted · 1 by the author only

See the evidence · Claim card